Deciphering Angiogenic Drivers in Hepatocellular Carcinoma: From Prognostic Signature Construction to Genistein‐Mediated Inhibition
Journal of Cellular and Molecular Medicine · 2026-05 · 30 (10)
DOI: 10.1111/jcmm.71203 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 24.05.2026. Verfasst von Hao Zheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery III, Guizhou Provincial People's Hospital, Guiyang, China. Hauptthemen laut MEDLINE: Genistein, Carcinoma, Hepatocellular, Liver Neoplasms, Neovascularization, Pathologic. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Science and Technology Foundation of Guizhou Provincial Health Commission, Doctoral Foundation of Guizhou Provincial People's Hospital.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is an aggressive malignancy with poor prognosis and a lack of reliable biomarkers. In this study, we integrated weighted gene co‐expression network analysis, machine‐learning‐based prognosticmodelling, single‐cell RNA sequencing, spatial transcriptomics, and molecular docking to identify angiogenesis‐related drivers in HCC. SCAF1 was identified as a hub gene and was significantly upregulated in HCC tissues compared with normal liver tissues. High SCAF1 expression was closely associated with advanced clinicopathological features and unfavourable survival outcomes. The prognostic model constructed by machine learning showed robust predictive performance in both training and validation cohorts, and decision curve analysis supported its clinical utility. Single‐cell and spatial transcriptomic analyses further suggested that SCAF1 was mainly associated with endothelial and immune‐related features of the tumour microenvironment. Functional assays showed that SCAF1 knockdown suppressed HCC cell migration, invasion, VEGFA expression, and angiogenic capacity in vitro. Mechanistically, SCAF1 was negatively correlated with anti‐angiogenic chemokines, including CCL19, CCL14, and CCL11, indicating a role in shaping a pro‐angiogenic microenvironment. In addition, molecular docking identified genistein as a promising compound with stable binding to SCAF1. Experimental validation showed that genistein reduced SCAF1 and VEGFA expression and inhibited HCC cell proliferation, migration, invasion, and tube formation. Collectively, these findings suggest that SCAF1 is a novel prognostic and angiogenesis‐related biomarker in HCC and a potential therapeutic target for genistein‐based intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery III, Guizhou Provincial People's Hospital, Guiyang, China.
- Second College of Clinical Medicine, Nanchang University, Nanchang, China.
- Department of Thyroid Surgery, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China.
Förderung
- the Science and Technology Foundation of Guizhou Provincial Health Commission
- Doctoral Foundation of Guizhou Provincial People's Hospital
Zitieren
APA
Zheng, H., Tang, S., Shi, R., Yu, Z., Zhang, R., Qu, X., Wan, H., Fang, C., Wang, X., Zhu, Y., Huang, D., & Chen, G. (2026). Deciphering Angiogenic Drivers in Hepatocellular Carcinoma: From Prognostic Signature Construction to Genistein‐Mediated Inhibition. Journal of Cellular and Molecular Medicine, 30(10). https://doi.org/10.1111/jcmm.71203
Vancouver
Zheng H, Tang S, Shi R, Yu Z, Zhang R, Qu X, et al. Deciphering Angiogenic Drivers in Hepatocellular Carcinoma: From Prognostic Signature Construction to Genistein‐Mediated Inhibition. Journal of Cellular and Molecular Medicine. 2026;30(10). doi:10.1111/jcmm.71203
BibTeX
@article{Zheng2026,
author = {Zheng, Hao and Tang, Shengwei and Shi, Ruida and Yu, Zichuan and Zhang, Ruiyu and Qu, Xiaoyu and Wan, Hao and Fang, Chenshuo and Wang, Xin and Zhu, Ye and Huang, Da and Chen, Gen},
title = {Deciphering Angiogenic Drivers in Hepatocellular Carcinoma: From Prognostic Signature Construction to Genistein‐Mediated Inhibition},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
volume = {30},
number = {10},
doi = {10.1111/jcmm.71203}
}
EUVIMED